Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma

• Status: Completed
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

A randomised, double-blind, double-dummy, placebo controlled multi-centre study to evaluate the efficacy and safety of fluticasone furoate inhalation powder and fluticasone propionate inhalation powder in the treatment of asthma in adults and adolescents not currently treated with inhaled corticosteroids

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Fluticasone; Xhance

Criteria

Inclusion Criteria:

• Signed informed consent

• Outpatient at least 12 years of age with a diagnosis of asthma at least 12 weeks prior to first visit

• Both genders; females of child bearing potential must be willing to use appropriate contraception during the study

• Pre-bronchodilator FEV1 of at least 60% predicted

• FEV1 reversibility of at least 12% and 200ml

• Current asthma therapy that includes a non-corticosteroid controller and/or short acting beta-agonist

Exclusion Criteria:

• History of life-threatening asthma exacerbation with the past 10 years

• Asthma exacerbation requiring oral corticosteroids within the past 3 months or overnight hospital stay within the past 6 months

• Current or recent respiratory infection or current oral candida infection

• Presence of a significant respiratory disease or other medical condition that is uncontrolled or that could affect subject safety or study outcome

• Known or suspected allergy to study medication or materials

• Taking another investigational medication or prohibited medication during the study

• Current smokers or former smokers with significant tobacco exposure

• Previous treatment with fluticasone furoate in a phase II or III study

• Children in Care